Innovatsii v kontratseptsii. Novyy kombinirovannyy oral'nyy kontratseptiv (obzor literatury)


Cite item

Full Text

Abstract

About the authors

V N Prilepskaya

References

  1. НоваРинг и Чарозетта в гинекологической практике: контрацептивы и их дополнительные лечебные свойства. Эффективная фармакотерапия. Акушерство и гинекология. 2011.
  2. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
  3. Gaussem P, Alhenc-Gelas M et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17b-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Schattauer 2011: 560-7.
  4. Agren UM et al. Eur J Contracept Reprod Health Care 2011.
  5. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2008; 1: CD003987. oi:10.1002/ 14651858. CD003987. pub 2.
  6. Speroff L, Fritz MA. Oral contraception. In: Clinical Gynecologic Endocrinology and Infertility; Philadelphia: Lippincott Williams & Wilkins, 2005: 861-942.
  7. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008; 61: 151-7.
  8. Martin, K, Barbieri R. Overview of the use of estrogen-progestogen contraceptives.
  9. Ouzounian S, Verstraete L, Chabbert-Buffet N. Third-generation oral contraceptives: future implications of current use. Exp Rev Obstet Gynecol 2008; 3 (2): 189-201.
  10. Westhoff C, Andrew M et al. Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17-Estradiol. A Randomized Controlled Trial. Obstet Gynecol 2012; 119 (5).
  11. Schindler A. Classification and pharmacology of progestins. Maturitas 2008; 61: 171-180.
  12. Alfred O. Mueck, Regine Sitruk-Ware. Nomegestrolacetate, a novelprogestogen for oral contraception. Steroids 76 2011; 531-9.
  13. Couzinet B et al. J Clin Endocrin Metab 1999; 84: 4191-6.
  14. Van Diepen HA et al. Contraception 2011; 84: 199-204.
  15. Mansour D et al. Eur J Contracept Reprod Health Care 2011.
  16. Fotherby K. Contraception 1996; 54: 59-69.
  17. Lobo RA et al. Am J Obstet Gynecol 1994; 170: 1499-507.
  18. Зоэли® summary of product characteristics. London, England: Merck Serono Europe Limited, 2011.
  19. Mansour D, Verhoeven C, Sommer W et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17b-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011.
  20. Wiegratz I, Hommel HH et al. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69 (1): 37-42.
  21. Coney P, Washenik K, Langley RGB et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63 (6): 297-302.
  22. Thiboutot D, Archer DF, Lemay A et al. A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertil Steril 2001; 76 (3): 461-8.
  23. Sibai BM, Odlind V, Meador ML et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho EvraTM/EvraTM). Fertil Steril 2002; 77 (Suppl. 2): S19-S26.
  24. Maloney JM, Dietze P, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112 (4): 773-81.
  25. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80 (6): 1816-21.
  26. Endrikat J, Sandri M, Gerlinger C et al. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 μg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care 2007; 12 (3): 220-8.
  27. Agren UM et al. Eur J Contracept Reprod Health Care 2011.
  28. Xiangyan Ruan, Helen Schneck et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012 [Epub].

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-63961 от 18.12.2015.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies